Some of these studies showed that the functional blockade of NF-κB or the inflammatory cytokines, such as TNF-α, IL-6 and IL-1β are a specific therapeutic strategy for the treatment of dystrophinopathies [11, 30–32]. Here, IL1B is linked to neuromuscular disease caused by qualitative or quantitative defects of dystrophin.